About Bioventix
Bioventix is a company based in Farnham (United Kingdom) founded in 2003. Bioventix offers products and services including SMAs, ELISA Kits, and Lateral Flow Assays. Bioventix operates in a competitive market with competitors including GenScript, Sino Biological, Epitomics, Y-Biologics and Mabtech, among others.
- Headquarter Farnham, United Kingdom
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Bioventix Plc
-
Annual Revenue
$17.97 M (USD)-3.61as on Jun 30, 2025
-
Net Profit
$10.38 M (USD)-6.33as on Jun 30, 2025
-
EBITDA
$13.52 M (USD)-7.86as on Jun 30, 2025
-
Latest Funding Round
Not available
-
Investors
Not available
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Bioventix
Bioventix is a publicly listed company on the LSE with ticker symbol BVXP in UK, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Bioventix
Bioventix offers a comprehensive portfolio of products and services, including SMAs, ELISA Kits, and Lateral Flow Assays.
Antibodies for optimizing blood-testing diagnostics.
Kits for detecting industrial pollutants in urine samples.
Assays for sensitive detection of small molecule targets.
Funding Insights of Bioventix
Detailed funding history for Bioventix
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Bioventix
Investment portfolio details for Bioventix
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Bioventix
Detailed financials for Bioventix
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Bioventix Comparisons
Peer comparison for Bioventix
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Bioventix
Bioventix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GenScript, Sino Biological, Epitomics, Y-Biologics and Mabtech, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Reagents and instruments are provided for life sciences research.
|
|
| Locked | Locked | Locked |
Reagents and kits are provided for clinical research applications.
|
|
| Locked | Locked | Locked |
Monoclonal antibody technology and products are developed by Epitomics.
|
|
| Locked | Locked | Locked |
Developer of antibodies for the treatment of multiple diseases
|
|
| Locked | Locked | Locked |
Antibodies and immunoassay kits are developed for research applications.
|
|
| Locked | Locked | Locked |
Antibody and vaccine culture media products are developed.
|
Detailed competitors of Bioventix
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Bioventix
Complete news archive for Bioventix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Bioventix
Bioventix was founded in 2003.
Bioventix is headquartered in Farnham, United Kingdom. It is registered at Farnham, Surrey, United Kingdom.
Annual revenue of Bioventix is $17.97M as on Jun 30, 2025.
Bioventix engages in producing sheep monoclonal antibody. The company produces affinity sheep monoclonal antibody using sheep hetero-myeloma fusion partner to immortalize B-cells. Antibodies produced here can be used in assays for analytes. Bioventis develops these recombinant antibodies for clinical diagnostic application and offers custom antibody development services against the target of choice.
Bioventix's top competitors include Sino Biological, GenScript and Y-Biologics.
Bioventix offers SMAs, ELISA Kits, and Lateral Flow Assays.
Yes, Bioventix is publicly traded on LSE under the ticker symbol BVXP.
The ticker symbol of Bioventix is BVXP on LSE.